Prevention Strategies — MCQs
The primary pharmacological intervention to retard avascular necrosis progression is?
What is the gold standard for the diagnosis of osteoporosis?
A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
A 60 year old woman is seen at an emergency room after she fractures the neck of her right femur during a minor fall. Radiologic studies demonstrate a generalized loss of bone mass. Exogenous therapy with which of the following hormones would have been most likely to slow or prevent the patient's bone disease?
Prevention or treatment of osteoporosis in post- menopausal women may be achieved by all EXCEPT
Minimum age for routine screening of osteoporosis in women according to USPSTF guidelines:
What is the recommended daily calcium intake for adult non-pregnant females?
Osteoporosis is seen in all the following except
Excess of calcium intake leads to?
Which of the following is the first-line management for postmenopausal women with osteoporosis?
Prevention Strategies Indian Medical PG Practice Questions and MCQs
Question 1: The primary pharmacological intervention to retard avascular necrosis progression is?
- A. High-dose calcium supplementation
- B. Vitamin D supplementation alone
- C. Corticosteroid therapy
- D. Bisphosphonates (Alendronate) (Correct Answer)
Explanation: ***Bisphosphonates (Alendronate)*** - **Bisphosphonates** inhibit osteoclast-mediated bone resorption and reduce bone cell death, showing promise in preventing progression of early-stage **avascular necrosis**. [1] - Alendronate specifically has been studied for its **bone-preserving effects** in AVN by maintaining bone architecture and potentially slowing femoral head collapse. *Corticosteroid therapy* - **Corticosteroids** are a major **risk factor** for developing avascular necrosis, not a treatment for it. - They cause AVN through mechanisms including **fat embolism**, increased **intraosseous pressure**, and direct **osteocyte toxicity**. *High-dose calcium supplementation* - **Calcium supplementation** supports general bone health but does not address the underlying **vascular disruption** in AVN. - No evidence exists that calcium alone can retard **AVN progression**, which involves interruption of blood supply leading to bone death. *Vitamin D supplementation alone* - **Vitamin D** is essential for calcium absorption and bone mineralization but does not target **AVN pathophysiology**. - Like calcium, it does not address the primary mechanism of **blood supply disruption** that characterizes avascular necrosis.
Question 2: What is the gold standard for the diagnosis of osteoporosis?
- A. Dual energy X-ray absorptiometry (Correct Answer)
- B. Single energy X-ray absorptiometry
- C. Ultrasound
- D. Quantitative computed tomography
Explanation: ***Dual energy X-ray absorptiometry*** - **DXA** is the current **gold standard** for diagnosing osteoporosis and assessing fracture risk due to its high precision and accuracy in measuring **bone mineral density (BMD)**. - It measures BMD at clinically relevant sites such as the **lumbar spine** and **hip**, providing T-scores and Z-scores for comparison. *Single energy X-ray absorptiometry* - **SXA** measures BMD at peripheral sites but is **less accurate** and comprehensive than DXA for diagnosing osteoporosis. - It has **limited utility** as a diagnostic tool for osteoporosis at the hip or spine, which are critical sites for fracture risk. *Ultrasound* - **Quantitative ultrasound (QUS)** can assess bone quality but is primarily used for **screening** and is not accurate enough for definitive diagnosis or treatment monitoring of osteoporosis. - It does **not provide direct bone mineral density measurements** comparable to DXA for diagnostic purposes. *Quantitative computed tomography* - **QCT** can measure volumetric bone density and is useful for assessing **trabecular bone**, but involves higher radiation exposure than DXA. - It is **more expensive** and less readily available than DXA, making it a secondary option for osteoporosis diagnosis.
Question 3: A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
- A. Oral vitamin D3 is given along with oral calcium
- B. Teriparatide should be started before supplementing bisphosphonates (Correct Answer)
- C. Calcium requirement is 1200 mg per day
- D. Bisphosphonates can be given for 3-5 years depending on patient response and risk factors
Explanation: ***Teriparatide should be started before supplementing bisphosphonates*** - This statement is incorrect because **bisphosphonates are typically the first-line treatment** for osteoporosis, especially in patients with a history of fragility fractures like a Colles fracture. - **Teriparatide**, an anabolic agent, is usually reserved for patients with very severe osteoporosis, those who have failed bisphosphonate therapy, or those with highly accelerated bone loss. *Oral vitamin D3 is given along with oral calcium* - This is a routine and **correct practice in osteoporosis management** as calcium and vitamin D are essential for bone health. - **Vitamin D** aids in calcium absorption from the gut, and both are crucial for bone mineralization and density. *Calcium requirement is 1200 mg per day* - The recommended daily **calcium intake for postmenopausal women** and elderly individuals with osteoporosis is typically around 1200 mg. - This amount helps to maintain skeletal health and reduce the risk of fractures. *Bisphosphonates can be given for 3-5 years depending on patient response and risk factors* - This statement is correct, as **bisphosphonates are commonly prescribed for 3-5 years** to reduce fracture risk in osteoporosis. - A **"drug holiday"** may be considered after this period, depending on the patient's fracture risk and bone mineral density.
Question 4: A 60 year old woman is seen at an emergency room after she fractures the neck of her right femur during a minor fall. Radiologic studies demonstrate a generalized loss of bone mass. Exogenous therapy with which of the following hormones would have been most likely to slow or prevent the patient's bone disease?
- A. Epinephrine
- B. Thyroxine
- C. Cortisol
- D. Estrogen (Correct Answer)
Explanation: ***Estrogen*** - **Estrogen deficiency** post-menopause is a primary cause of **osteoporosis** in women due to increased osteoclast activity and bone resorption. - **Exogenous estrogen therapy** could have helped prevent bone loss by inhibiting osteoclast activity and promoting osteoblast function. *Epinephrine* - **Epinephrine** is a catecholamine primarily involved in the **fight-or-flight response**, affecting cardiovascular function and metabolism. - It does not have a direct therapeutic role in preventing **generalized bone mass loss** or treating osteoporosis. *Thyroxine* - **Thyroxine (thyroid hormone)**, especially in excess, can actually accelerate bone turnover and lead to **bone loss** and increased fracture risk. - It is not used to prevent osteoporosis; managing thyroid dysfunction is crucial to bone health. *Cortisol* - **Cortisol** is a glucocorticoid that, when in excess (e.g., in Cushing's syndrome or long-term steroid use), can cause **osteoporosis** by inhibiting bone formation and increasing bone resorption. - Therefore, exogenous cortisol would exacerbate, not prevent, the patient's bone disease.
Question 5: Prevention or treatment of osteoporosis in post- menopausal women may be achieved by all EXCEPT
- A. Calcium and vitamin D supplementation
- B. Multivitamins (Correct Answer)
- C. Bisphosphonates
- D. Estrogen and progesterone hormone replacement therapy
Explanation: ***Multivitamins*** - While multivitamins may contain some **calcium** and **vitamin D**, the dosages are generally insufficient to effectively prevent or treat osteoporosis, which requires targeted, higher doses of these specific nutrients. - Multivitamins provide a broad range of vitamins and minerals, many of which are not directly involved in **bone metabolism** or have a significant impact on **bone mineral density**. *Calcium and vitamin D supplementation* - **Calcium** is a fundamental component of bone, and adequate intake is crucial for maintaining **bone mineral density** and strength, especially in postmenopausal women who are at higher risk of osteoporosis [1, 4]. - **Vitamin D** is essential for the absorption of calcium in the gut and plays a key role in regulating **calcium and phosphate homeostasis**, directly impacting bone health [3]. *Bisphosphonates* - **Bisphosphonates** are potent **antiresorptive agents** that inhibit **osteoclast activity**, thereby reducing bone turnover and preventing bone loss, making them a cornerstone of osteoporosis treatment. - They effectively increase **bone mineral density** and significantly reduce the risk of **vertebral and non-vertebral fractures** in postmenopausal women. *Estrogen and progesterone hormone replacement therapy* - **Estrogen deficiency** after menopause is a primary cause of accelerated bone loss; **estrogen replacement therapy** helps to maintain bone density by reducing **bone resorption** [2]. - While effective, HRT is typically reserved for women with significant menopausal symptoms or those who cannot tolerate other osteoporosis treatments, due to potential risks like increased risk of **breast cancer** and **cardiovascular events** [2].
Question 6: Minimum age for routine screening of osteoporosis in women according to USPSTF guidelines:
- A. 55 years
- B. 60 years
- C. 50 years
- D. 65 years (Correct Answer)
Explanation: ***65 years*** - The **U.S. Preventive Services Task Force (USPSTF)** recommends routine osteoporosis screening with **bone mineral density (BMD) testing** for all women aged 65 years and older. - This recommendation is based on evidence that screening in this age group can effectively reduce the risk of **osteoporotic fractures**. *55 years* - This age is **too early** for routine osteoporosis screening in women according to current USPSTF guidelines. - Screening before age 65 is recommended only for younger women at **increased risk** of osteoporosis. *60 years* - This age is also **too early** for routine osteoporosis screening in women without additional risk factors. - The benefits of universal screening typically outweigh the harms beginning at age 65. *50 years* - This age is generally considered **too young** for routine osteoporosis screening. - Women in this age group are often still premenopausal or early postmenopausal and typically do not have a sufficiently high risk to warrant routine screening.
Question 7: What is the recommended daily calcium intake for adult non-pregnant females?
- A. 1000 mg (Correct Answer)
- B. 1200 mg
- C. 600 mg
- D. 800 mg
Explanation: ***1000 mg*** - The recommended daily calcium intake for adult non-pregnant females (ages 19-50) is **1000 mg** according to **WHO and international guidelines** (US RDA/NIH) to maintain bone health and prevent osteoporosis. - This is the **standard recommendation** used in most medical textbooks and international nutritional guidelines. - Adequate calcium intake supports various bodily functions, including **nerve transmission**, **muscle contraction**, and **hormone secretion**. *1200 mg* - While 1200 mg is the recommended intake for **older women (above 50-70 years)** or during **pregnancy/lactation** per some guidelines, it is generally higher than necessary for non-pregnant adult females aged 19-50. - While not harmful, this higher dose is not specifically indicated for the general non-pregnant adult female population. *600 mg* - This amount of calcium is **lower than the internationally recommended daily allowance** for adult women (though it aligns with some regional guidelines like ICMR for sedentary women). - For optimal bone health and prevention of osteoporosis, **1000 mg is the widely accepted standard** in medical education. *800 mg* - This value is **below the internationally recommended daily intake** for adult non-pregnant females, which could lead to long-term calcium deficiency. - Insufficient calcium intake can increase the risk of conditions like **osteopenia** and **osteoporosis**.
Question 8: Osteoporosis is seen in all the following except
- A. Steroid therapy
- B. Rheumatoid arthritis
- C. Thyrotoxicosis
- D. Hypoparathyroidism (Correct Answer)
Explanation: ***Hypoparathyroidism*** - Hypoparathyroidism leads to low levels of **parathyroid hormone (PTH)**, which causes **hypocalcemia** and **hyperphosphatemia**. - This condition is associated with **increased bone density** and sometimes osteosclerosis, rather than osteoporosis. *Steroid therapy* - **Glucocorticoids** inhibit osteoblast function and promote osteoclast activity, leading to **bone demineralization** and osteoporosis [1]. - This is a common cause of secondary osteoporosis, especially with long-term systemic use [1]. *Rheumatoid arthritis* - **Chronic inflammation** in rheumatoid arthritis contributes to generalized bone loss and osteoporosis [1]. - Additionally, patients often receive **glucocorticoid treatment**, which further exacerbates bone loss [1]. *Thyrotoxicosis* - **Excessive thyroid hormone** directly stimulates bone remodeling, increasing both bone formation and resorption. - However, the increase in **resorption outpaces formation**, leading to overall bone loss and a higher risk of osteoporosis.
Question 9: Excess of calcium intake leads to?
- A. Cardiomyopathy
- B. Osteomalacia
- C. Osteoporosis
- D. Milk alkali syndrome (Correct Answer)
Explanation: ***Milk alkali syndrome*** - **Milk-alkali syndrome** is caused by excessive intake of calcium (especially in the form of calcium carbonate) and absorbable alkali, leading to **hypercalcemia**, metabolic alkalosis, and acute kidney injury. - The combination of abnormally high calcium intake, often from supplements, and the use of antacids or milk, drives this condition. *Cardiomyopathy* - **Cardiomyopathy** refers to diseases of the heart muscle that make it harder for the heart to pump blood, and it is not directly caused by excess calcium intake. - While severe hypercalcemia can affect cardiac function, it typically causes arrhythmias or altered contractility, not a primary **cardiomyopathy**. *Osteomalacia* - **Osteomalacia** is a softening of the bones, typically due to **vitamin D deficiency** or impaired metabolism, leading to inadequate mineralization of new bone matrix. - This condition is caused by insufficient calcium and phosphate for normal bone formation, not by an **excess of calcium intake**. *Osteoporosis* - **Osteoporosis** is a disease where bones become weak and brittle due to **loss of bone mass** and microarchitectural deterioration. [1] - Chronic excess calcium intake does not cause osteoporosis; in fact, adequate calcium intake is crucial for **bone health** and preventing osteoporosis. [1]
Question 10: Which of the following is the first-line management for postmenopausal women with osteoporosis?
- A. Calcitonin
- B. Raloxifene
- C. Tamoxifen
- D. Bisphosphonates (Correct Answer)
Explanation: ***Bisphosphonates*** - **Bisphosphonates** are the **first-line therapy** for postmenopausal osteoporosis due to their proven efficacy in reducing the risk of fragility fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Calcitonin* - **Calcitonin** is a hormone that inhibits bone resorption, but its **anti-fracture efficacy is weaker** than bisphosphonates. - It is typically used as a **second-line agent** or for patients who cannot tolerate bisphosphonates, often for its analgesic effect in vertebral compression fractures. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that mimics estrogen's beneficial effects on bone. - While it helps prevent vertebral fractures, it is **less effective than bisphosphonates** at preventing non-vertebral fractures and carries a risk of venous thromboembolism. *Tamoxifen* - **Tamoxifen** is also a **SERM**, primarily used in the treatment of **estrogen receptor-positive breast cancer**. - While it has **estrogen-like effects on bone** and can improve bone density, it is not approved or routinely used for the primary management of osteoporosis due to its other systemic effects and risks.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free